Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 6:15 PM ET


Company Overview of Hydra Biosciences, Inc.

Company Overview

Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.

45 Moulton Street

Cambridge, MA 02138

United States

Founded in 2001





Key Executives for Hydra Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 56
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder, Chair of Scientific Advisory Board and Member of Pain Medical Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.

Hydra Biosciences, Inc. Key Developments

Hydra Biosciences Announces the Formation of a Pulmonary Medical Advisory Board

Hydra Biosciences announced the formation of a Pulmonary Medical Advisory Board. Three experts in pulmonary medicine, Dr. William Busse, Dr. Paul O’Byrne and Dr. Sven-Erik Dahlén, were appointed to the board. The three members of the advisory board are leaders in allergy and immunology, asthma and pulmonology: William W. Busse, M.D., is professor of Medicine at the University of Wisconsin Medical School, where he has taught since 1974 and has served as head of the Allergy and Clinical Immunology Division and Chair of Medicine. Paul O’Byrne, M.D., is the E. J. Moran Campbell Professor of Medicine and Chair of the Department of Medicine at the Michael G. DeGroote School of Medicine at McMaster University. He is also the executive director of the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare. Sven-Erik Dahlén, M.D., Ph.D., is a professor of experimental asthma and allergy research and the director of the Centre for Allergy Research at Karolinska Institutet in Stockholm. He has held many positions and appointments in pulmonary medicine, including serving as the Scientific Advisor for the Swedish Public Health Institute and on multiple boards at the Karolinska Institutet.

Hydra Biosciences Announces Executive Appointments to Newly Created Pain Medical Advisory Board

Hydra Biosciences announced newly formed pain medical advisory board (MAB) with the appointments of three leading physicians and scientists, Dr. Robert Dworkin, Dr. Roy Freeman and Dr. Nathaniel Katz. Dr. Paul Goldenheim, member of the Hydra Biosciences Board of Directors and Hydra founder, Dr. David Clapham, chair of the Hydra Scientific Advisory Board, also have seats on the MAB, which will provide clinical and scientific guidance as Hydra continues to develop HX-100, its clinical stage TRPA1 antagonist, in painful diabetic neuropathy. Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry in the Center for Human Experimental Therapeutics, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Roy Freeman, M.D., is a professor of neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston. Dr. Freeman also is chairman of the World Federation of Neurology research group on the autonomic nervous system. Nathaniel Katz, a neurologist and pain management specialist with a distinguished career spanning Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Katz also served as Chair of the Advisory Committee, Anesthesia, Critical Care and Addiction Products Division for the FDA.

Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM

Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Morria Biopharmaceuticals Inc. United States
Galderma Laboratories, L.P. United States
NeuroSystec Corporation United States
Wyeth Holdings Corporation United States
Avanir Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
March 17, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hydra Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at